Urol. praxi. 2016;17(5):206-209 | DOI: 10.36290/uro.2016.053

Adrenocortical carcinoma

MUDr.Igor Hartmann, Ph.D.1, MUDr.Filip Čtvrtlík, Ph.D.2, doc.MUDr.Zdeněk Fryšák, CSc.3, doc.MUDr.Martin Doležel, Ph.D.4,5, MUDr.Pavel Rajmon1, doc.MUDr.Vladimír Študent, Ph.D.1
1 Urologická klinika FN a LF UP, Olomouc
2 Radiologická klinika FN a LF UP, Olomouc
3 3. interní klinika NRE, FN a LF UP, Olomouc
4 Onkologická klinika FN a LF UP, Olomouc
5 KOC Pardubická krajská nemocnice a.s. a Multiscan s.r.o., Pardubice

Adrenocortical carcinoma is a relatively rare, but very malignant disease. Complete surgical removal of tumour tissue is the

only chance for the patient. Other treatment methods fail to result in satisfactory outcomes. Therefore, early disease diagnosis

is essential that is based on a close collaboration of the endocrinologist, radiologist, and surgeon. The review article discusses

the fundamental principles of the diagnostic and therapeutic process, with emphasis being placed on utilization in the practice.

Keywords: adrenocortical carcinoma

Published: December 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hartmann I, Čtvrtlík F, Fryšák Z, Doležel M, Rajmon P, Študent V. Adrenocortical carcinoma. Urol. praxi. 2016;17(5):206-209. doi: 10.36290/uro.2016.053.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Grumbach MM, Biller BM, Braunstein GD, Campbell KK, Carney JA, Godley PA, Harris EL, Lee JK, Oertel YC, Posner MC, Schlechte JA, Wieand HS. Management of the clinically inapparent adrenal mass (incidentaloma). Ann Intern Med 2003; 138: 424-429. Go to original source... Go to PubMed...
    2. Wajchenberg B, Albergaria PM, Medonca B, Latronico A, Campos CP, Ferreira AV, Zerbini M, Liberman B, Carlos GG, Kirschner M. Adrenocortical carcinoma: clinical and laboratory observations. Cancer 2000; 88: 711-736. Go to original source...
    3. Dackiw AP, Lee JE, Gagel RF, Evans DB. Adrenal cortical carcinoma. World J Surg 2001; 25: 914-926. Go to original source... Go to PubMed...
    4. http://www.svod.cz
    5. Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, Laudat MH, Louvel A, Chapuis Y, Blondeau P, Bonnin A, Bricaire H. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990; 322: 1195-1201. Go to original source... Go to PubMed...
    6. Wooten MD, King DK. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer. 1993; 72: 3145-3155. Go to original source...
    7. Koschker AK, Fassnacht M, Hahner S, Weismann D, Allolio B. Adrenocortical carcinoma: improving patient care by establishing new structures. Exp Clin Endocrinol Diabetes. 2006; 114: 45-51. Go to original source... Go to PubMed...
    8. Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, Giovagnetti M, Opocher G, Angeli A. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 2000; 85: 637-644. Go to original source...
    9. Kasperlik-Zeluska AA, Roslonowska E, Slowinska-Srzednicka J, Migdalska B, Jeske W, Makowska A, Snochowska H. Incidentally discovered adrenal mass (incidentaloma): investigation and management of 208 patients. Clin Endocrinol (Oxf). 1997; 46: 29-37. Go to original source... Go to PubMed...
    10. Seccia TM, Fassina A, Nussdorfer GG, Pessina AC, Rossi GP. Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. Endocr Relat Cancer. 2005; 12: 149-159. Go to original source... Go to PubMed...
    11. National Institutes of Health. NIH state-of-the-science statement on management of the clinically inapparent adrenal mass (incidentaloma). NIH Consens State Sci Statements. 2002; 19: 1-252.
    12. Dackiw AP, Lee JE, Gagel RF, Evans DB. Adrenal cortical carcinoma. World J Surg. 2001; 25: 914-926. Go to original source... Go to PubMed...
    13. Boland GW, Lee MJ, Gazelle GS, Halpern EF, McNicholas MM, Mueller PR. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol. 1998; 171: 201-204. Go to original source... Go to PubMed...
    14. Hamrahian AH, Ioachimescu AG, Remer EM, Motta-Ramirez G, Bogabathina H, Levin HS, Reddy S, Gill IS, Siperstein A, Bravo EL. Clinical utility of noncontrast computed tomography attenuation value (Hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. J Clin Endocrinol Metab. 2005; 90: 871-877. Go to original source... Go to PubMed...
    15. Outwater EK, Siegelman ES, Huang AB, Birnbaum BA. Adrenal masses: correlation between CT attenuation value and chemical shift ratio at MR imaging with in-phase and opposed-phase sequences. Radiology. 1996; 200: 749-752. Go to original source... Go to PubMed...
    16. Bilbey JH, McLoughlin RF, Kurkjian PS, Wilkins GE, Chan NH, Schmidt N, Singer J. MR imaging of adrenal masses: value of chemical-shift imaging for distinguishing adenomas from other tumors. AJR Am J Roentgenol. 1995; 164: 637-642. Go to original source... Go to PubMed...
    17. Korobkin M, Lombardi TJ, Aisen AM, Francis IR, Quint LE, Dunnick NR, Londy F, Shapiro B, Gross MD, Thompson NW. Characterization of adrenal masses with chemical shift and gadolinium-enhanced MR imaging. Radiology. 1995; 197: 411-418. Go to original source... Go to PubMed...
    18. Weiss LM, Medeiros LJ, Vickery Jr AL. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol. 1989; 13: 202-206. Go to original source... Go to PubMed...
    19. DeLellis RA, Lloyd RV, Heitz PU, Eng C. World Health Organization classification of tumours. Pathology and genetics of tumours of endocrine organs. Lyon, France; IARC Press. 2004.
    20. Lee JE, Berger DH, el-Naggar AK, Hickey RC, Vassilopoulou-Sellin R, Gagel RF, Burgess MA, Evans DB. Surgical management, DNA content, and patient survival in adrenal cortical carcinoma. Surgery. 1995; 118: 1090-1098. Go to original source... Go to PubMed...
    21. Porpiglia F, Miller BS, Manfredi M, Fiori C, Doherty GM. A debate on laparoscopic versus open adrenalectomy for adrenocortical carcinoma. Horm Cancer. 2011; 2(6): 372-327. doi: 10.1007/s12672-011-0095-1. Go to original source... Go to PubMed...
    22. Cobb WS, Kercher KW, Sing RF, Heniford BT. Laparoscopic adrenalectomy for malignancy. Am J Surg. 2005; 189: 405-411. Go to original source... Go to PubMed...
    23. Gonzalez RJ, Shapiro S, Sarlis N, Vassilopoulou-Sellin R, Perrier ND, Evans DB, Lee JE. Laparoscopic resection of adrenal cortical carcinoma: a cautionary note. Surgery. 2005; 138(6): 1078-1085; discussion 1085-1086. Go to original source... Go to PubMed...
    24. Leboulleux S, Deandreis D, Ghuzlan A, Aupérin A, Goéré D, Dromain C, Elias D, Caillou B, Travagli JP, De Baere T, Lumbroso J, Young J, Schlumberger M, Baudin E. Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis? Eur J Endocrinol. 2010; 162(6): 1147-1153. Go to original source... Go to PubMed...
    25. Brix D, Allolio B, Fenske W, Agha A, Dralle H, Jurowich C, Langer P, Mussack T, Nies C, Riedmiller H, Spahn M, Weismann D, Hahner S, Fassnacht M; German Adrenocortical Carcinoma Registry Group. Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients.Eur Urol. 2010; 58(4): 609-615. Go to original source... Go to PubMed...
    26. Jensen JC, Pass HI, Sindelar WF, Norton JA. Recurrent or metastatic disease in select patients with adrenocortical carcinoma. Aggressive resection vs chemotherapy. Arch Surg. 1991; 126: 457-461. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.